2023-07-01 05:24:00
[시사저널e=노경은 기자] It was revealed that Hyundai Pharm had distributed an Alzheimer’s disease treatment drug in a medicine cabinet for hypertension treatment and entered into a recall.
According to the Ministry of Food and Drug Safety on the 1st, on the 23rd of last month, the Ministry of Food and Drug Safety ordered Hyundai Pharm to recall Hyundai Minoxidil Tablets (ingredient: minoxidil) with serial number 23018 produced on the 15th of last month. The Ministry of Food and Drug Safety explained the reason for the recall as “a business operator’s recall due to some labeling of other products being attached to the packaging container.”
Minoxidil is a drug used to treat high blood pressure and hair loss. Tablets to be eaten are used as a treatment for high blood pressure due to their vasodilator action, and 2-5% external tablets are used as a treatment for hair loss due to their ability to promote hair production.
The problem this time is the tablets to eat. Although it has the effect of lowering blood pressure due to its strong vasodilator effect, it has side effects such as congestive heart failure and tachycardia.
However, Hyundai Pharmaceutical put Tamirin (Galatamine), an Alzheimer’s disease drug, which is a completely different ingredient in the minoxidil tablet medicine cabinet during the factory production process. Tamirin Tab is a prescription drug produced by Hyundai Pharm as a treatment for symptoms of mild to moderate dementia in the form of Alzheimer’s disease. The size and shape of the barrels used by the two drugs are the same and are produced on the same process line, and both drugs are white tablets with a diameter of 6.5 mm and are difficult to distinguish with the naked eye except for the engraved ingredient names, which seems to be a mistake.
After confirming this fact, Hyundai Pharm launched an emergency recall. The announcement on the recall was announced on the website, etc., and the drug dealers, pharmacies, and medical institutions that stored the drugs immediately stopped selling them and requested the recall obligor (Hyundai Pharm) to return them. It is reported that the target of this recovery is about 20,000 bottles.
In this regard, the Daejeon Regional Food and Drug Administration is investigating how the product went wrong and whether consumers took it.
The risk of this recovery was rated as Level 1. The risk level is divided into grades 1 to 3, and grade 1 refers to cases in which problems in the safety and effectiveness of drugs are directly related to life. ▲ Cases where the use of drugs, etc. causes serious side effects that cannot be cured or leads to death ▲ Cases where fatal ingredients are mixed ▲ Cases that may affect life due to incorrect labeling of drugs, etc.
However, Hyundai Pharm said that it has not yet been identified that there are no consumers who have taken the medicine incorrectly due to manufacturing problems.
1688208133
#Hyundai #Pharm #put #dementia #medicine #medicine #cabinet #high #blood #pressure #mistake.. #Recovering #bottles